| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 70 |
| Referral date | 01 November 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | Aberdeen HTA Group |
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 14 April 2010 |
As you are aware, the Department of Health has asked us to carry out a single technology appraisal of pazopanib for the second line treatment of metastatic renal cell carcinoma, following the publication of the Cancer Reform Strategy.This appraisal began, in January 2010, with a consultation on the draft scope and provisional matrix. Ministers have considered developments since this product was originally referred to NICE, including information received from the manufacturer in relation to this indication and the number of patients who may be eligible to receive pazopanib for the second-line treatment of mRCC in the future. As a result Ministers have now agreed that this topic should be removed from the NICE work programme. If you have any questions, please contact the project manager for this appraisal, Cathryn Hall,on telephone number 020 7045 2240 or at email address cathryn.hall@nice.org.uk |
For further information on our processes and methods, please see our CHTE processes and methods manual